In Brief: Endo Buys Somar; Neptune, Enzymotec Settle Dispute; FDA Prohibits Omega-3 Nutrient Claims
This article was originally published in The Tan Sheet
Endo buys Somar; Neptune, Enzymotec settle patent infringement; FDA prohibits omega-3 nutrient claims; “Sell through” for herbals ends in U.K.; C&D licenses Nutrition 21’s chromium picolinate; Arizona DXM bill and Iowa Select Herbs drug claims.
You may also be interested in...
The settlement terms are confidential, but Pfizer “acknowledged the validity of Nutrition 21’s asserted patents” and the Centrum line “may continue to use chromium picolinate,” Nutrition 21 says. The firms agreed as attorneys prepared to begin questioning a pool of potential jurors for the trial.
The small central African country has been chosen to host the planned African Medicines Agency and is also set to be a key player in medicines and vaccines manufacturing technology on the continent.
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.